Knight Therapeutics Inc. Q3 2025 Earnings Recap

GUD.TO Q3 2025 November 7, 2025

Get alerts when GUD.TO reports next quarter

Knight Therapeutics reported its strongest financial results to date for Q3 2025, achieving record revenues of $122.6 million, driven by significant growth from its oncology portfolio and strategic acquisitions.

Earnings Per Share Miss

$-0.04 vs $0.01 est.

-480.4% surprise

Revenue Beat

121548000 vs 118187000 est.

+2.8% surprise

Market Reaction

1-Day -0.33%

5-Day +1.32%

30-Day -2.14%

See GUD.TO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted revenue rose 34% year-over-year, with a notable contribution of $25 million from the Paladin and Sumitomo portfolios.
Adjusted EBITDA reached $49 million for the first nine months of 2025, demonstrating robust operational efficiency.
Successful launches of three new products in key markets, including JORNAY PM in Canada and MINJUVI in Argentina, bolstered the revenue stream.
Despite setbacks with TAVALISSE and Qelbree regulatory submissions, the company remains committed to addressing regulatory requirements.
Knight initiated a Normal Course Issuer Bid (NCIB) to repurchase up to 3 million shares, enhancing shareholder value.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GUD.TO on AllInvestView.

Previous Q2 2025

Next Q1 2026